291509-61-0

Basic information

• Product Name: 1,3,4,5-Tetrahydro-3-(4-piperidinyl)-2H-1,3-benzodiazepin-2-one
• Synonyms: 1,3,4,5-Tetrahydro-3-(4-piperidinyl)-2H-1,3-benzodiazepin-2-one;3-(Piperidin-4-yl)-2,3,4,5-tetrahydro-1H-1,3-benzodiazepin-2-one;3-(PIPERIDIN-4-YL)-4,5-DIHYDRO-1H-BENZO[D][1,3]DIAZEPIN-2(3H)-ONE
• CAS NO: 291509-61-0
• Molecular Formula: C₁₄H₁₉N₃O
• Molecular Weight: 245.33
• Mol File: 291509-61-0.mol

Chemical Properties

• Boiling Point: 468.6°C at 760 mmHg
• Flash Point: 237.2°C
• Appearance: /
• Density: 1.147g/cm³
• Vapor Pressure: 5.92E-09mmHg at 25°C
• Refractive Index: 1.568
• CAS DataBase Reference: 1,3,4,5-Tetrahydro-3-(4-piperidinyl)-2H-1,3-benzodiazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,4,5-Tetrahydro-3-(4-piperidinyl)-2H-1,3-benzodiazepin-2-one(291509-61-0)
• EPA Substance Registry System: 1,3,4,5-Tetrahydro-3-(4-piperidinyl)-2H-1,3-benzodiazepin-2-one(291509-61-0)

Safety Data

• Hazardous Substances Data: 291509-61-0(Hazardous Substances Data)

Usage

Class

Psychoactive drug

Effects

Anxiolytic (reduces anxiety) and tranquilizing

Medication Class

Benzodiazepine

Indications

Treating anxiety disorders and insomnia

Mechanism of Action

Enhances the activity of gamma-aminobutyric acid (GABA) in the brain

Result of Mechanism

Decreased anxiety and muscle tension

Tolerability

Generally well-tolerated

Sedation Risk

Lower risk of sedation compared to other benzodiazepines

Dependence Risk

Lower risk of dependence compared to other benzodiazepines

Medical Approval

Approved for medical use in certain countries

Availability

Not widely available

United States Approval

Not approved for use in the United States

InChI:InChI=1/C14H19N3O/c18-14-16-13-4-2-1-3-11(13)7-10-17(14)12-5-8-15-9-6-12/h1-4,12,15H,5-10H2,(H,16,18)

Upstream product

• 15121-84-3 2-nitro-benzeneethanol 
• 579-71-5 2-nitrostyrene 
• 773886-91-2 [2-(2-aminophenyl)-ethyl]-(1-benzyl-piperidin-4-yl)-amine 
• 874570-85-1 (1-benzyl-piperidin-4-yl)-[2-(2-nitrophenyl)-ethyl]-amine 
• 773886-92-3 3-(1-benzylpiperidin-4-yl)-1,3,4,5-tetrahydro-2H-benzo[d][1,3]diazepin-2-one 
• 783368-37-6 tert-butyl 4-(1,2,4,5-tetrahydro-2-oxobenzo[d][1,3]diazepin-3-yl)piperidine-1-carboxylate 

Downstream Products

• 910575-68-7 (R)-3-(3-chloro-4-hydroxy-5-methyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid 
• 910575-97-2 (S)-2-(3-chloro-4-hydroxy-5-trifluoromethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-butanoic acid 
• 910575-52-9 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-2-(4-benzyloxy-3-ethyl-5-methyl-phenyl)-1-carboxy-ethyl ester 
• 910576-01-1 (S)-2-(4-benzyloxy-3,5-dimethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-butanoic acid 
• 910576-02-2 (S)-2-(4-hydroxy-3,5-dimethyl-benzyl)-4-oxo-4-[4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidin-1-yl]-butanoic acid 
• 910575-53-0 4-(2-oxo-1,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylic acid (R)-1-carboxy-2-(3-ethyl-4-hydroxy-5-methyl-phenyl)-ethyl ester 
• 1554114-37-2 C₃₉H₅₅FN₆O₃S 
• 1554114-40-7 C₃₉H₅₅FN₆O₃S 

Relevant articles and documents

Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists

Calcitonin gene-related peptide (CGRP) receptor antagonists have been shown clinically to be effective treatments for migraine. Zavegepant (BHV-3500, BMS-742413) is a high affinity antagonist of the CGRP receptor (hCGRP Ki = 0.023 nM) that has

NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS

The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.

CGRP ANTAGONISTS

The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

3-(4-PIPERIDINYL)-2,3,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-2(1H)-ON

The present invention relates to a process for preparing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one of formula which is to be found as a structural element in CGRP antagonists which are suitable above all for the oral th

CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS

The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.

3-(4-PIPERIDINYL)-2,3,4,5-TETRAHYDRO-1,3-BENZODIAZEPIN-2(1H)-ONE

The present invention relates to a process for preparing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1-one of formula which is to be found as a structural element in CGRP-antagonists, which are particularly suitable for the oral

BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: I (where variables R1, R2, R3, R6, R7, G, J, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Calcitonin gene related peptide receptor antagonists

The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.